Sverige - svenska - Läkemedelsverket (Medical Products Agency)

reddy holding gmbh - fingolimodhydroklorid - kapsel, hård - 0,5 mg - natriumlaurilsulfat hjälpämne; betadex hjälpämne; fingolimodhydroklorid 0,56 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

pensa pharma ab - fingolimodhydroklorid - kapsel, hård - 0,5 mg - fingolimodhydroklorid 0,56 mg aktiv substans; propylenglykol hjälpämne

Europeiska unionen - svenska - EMA (European Medicines Agency)

eli lilly nederland b.v. - necitumumab - carcinom, non-small cell lung - antineoplastiska medel - portrazza i kombination med gemcitabin och cisplatin kemoterapi är indicerat för behandling av vuxna patienter med lokalt avancerad eller metastaserad epidermal tillväxtfaktor (egfr) uttrycker skivepitelcancer icke-småcellig lungcancer som inte har tidigare fått kemoterapi för detta tillstånd.

Europeiska unionen - svenska - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - multipel skleros - selektiva immunsuppressiva medel - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 och 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Europeiska unionen - svenska - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunsuppressiva - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 och 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

meda ab - mitoxantronhydroklorid - koncentrat till infusionsvätska, lösning - 2 mg/ml - natriummetabisulfit hjälpämne; mitoxantronhydroklorid 2,328 mg aktiv substans - mitoxantron

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ebewe pharma ges.m.b.h.nfg.kg - mitoxantronhydroklorid - koncentrat till infusionsvätska, lösning - 2 mg/ml - mitoxantronhydroklorid 2,328 mg aktiv substans - mitoxantron

Europeiska unionen - svenska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod hydroklorid - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunsuppressiva - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Europeiska unionen - svenska - EMA (European Medicines Agency)

mylan ireland limited - dimetylfumarat - multipel skleros, skovvis förlöpande - immunsuppressiva - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Europeiska unionen - svenska - EMA (European Medicines Agency)

zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimetylfumarat - multipel skleros, skovvis förlöpande - immunsuppressiva - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.